Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Biocad
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
67Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06987851CT.gov An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD | — | Completed | — | — | — |
NCT05385744CT.gov An International, Multicenter, Randomized, Double-Blind, Double-Masked Study of the Efficacy and Safety of BCD-132 (JSC BIOCAD, Russia) Using an Active Reference Drug (Teriflunomide) for the Treatment of Patients With Multiple Sclerosis | — | Completed | — | — | — |
NCT04056897CT.gov Comparative Study of the Efficacy and Safety of BCD-132 With Teriflunomide and Placebo in Multiple Sclerosis | — | Completed | — | — | — |
NCT03551275CT.gov Dose Escalation Study of the Pharmacodynamics, Pharmacokinetics, Safety, and Immunogenicity of BCD-132 in Patients With Relapsing-Remitting Multiple Sclerosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Divozilimab (this asset) | Biocad | P3 | BB · 66 |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Natalizumab | Biogen | P4 | BB |
| Fingolimod | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Divozilimab in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/divozilimab-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →